Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome

Ayalew Tefferi; Michelle A. Elliott; David P. Steensma; C. Christopher Hook; Angela Dispenzieria; Curtis A. Hanson; Georgene Schroeder; Louis Letendre

doi:10.1016/S0145-2126(00)00108-9

Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome

Ayalew Tefferi, Michelle A. Elliott, David P. Steensma, C. Christopher Hook, Angela Dispenzieria, Curtis A. Hanson, Georgene Schroeder, Louis Letendre

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Ten anemic patients with favorable myelodysplastic syndrome (MDS) were first treated with two 5-week courses of amifostine alone (each course consisted of 200 mg/m² of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks). The study patients either had previously failed to respond to treatment with EPO or had pretreatment serum EPO levels of more than 100 mU/ml. None of the patients experienced a complete or partial response in anemia or other cytopenias. We conclude that amifostine alone or in combination with EPO has limited therapeutic activity in MDS.

Original language	English (US)
Pages (from-to)	183-185
Number of pages	3
Journal	Leukemia Research
Volume	25
Issue number	2
DOIs	https://doi.org/10.1016/S0145-2126(00)00108-9
State	Published - 2001

Keywords

Amifostine
Anemia
Cytopenia
Differentiating therapy
Erythropoietin
Myelodysplastic syndromes

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/S0145-2126(00)00108-9

Cite this

@article{79ebb77680ab43caa4fad02a9cd0d25a,

title = "Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome",

abstract = "Ten anemic patients with favorable myelodysplastic syndrome (MDS) were first treated with two 5-week courses of amifostine alone (each course consisted of 200 mg/m2 of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks). The study patients either had previously failed to respond to treatment with EPO or had pretreatment serum EPO levels of more than 100 mU/ml. None of the patients experienced a complete or partial response in anemia or other cytopenias. We conclude that amifostine alone or in combination with EPO has limited therapeutic activity in MDS.",

keywords = "Amifostine, Anemia, Cytopenia, Differentiating therapy, Erythropoietin, Myelodysplastic syndromes",

author = "Ayalew Tefferi and Elliott, {Michelle A.} and Steensma, {David P.} and Hook, {C. Christopher} and Angela Dispenzieria and Hanson, {Curtis A.} and Georgene Schroeder and Louis Letendre",

year = "2001",

doi = "10.1016/S0145-2126(00)00108-9",

language = "English (US)",

volume = "25",

pages = "183--185",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome

AU - Tefferi, Ayalew

AU - Elliott, Michelle A.

AU - Steensma, David P.

AU - Hook, C. Christopher

AU - Dispenzieria, Angela

AU - Hanson, Curtis A.

AU - Schroeder, Georgene

AU - Letendre, Louis

PY - 2001

Y1 - 2001

N2 - Ten anemic patients with favorable myelodysplastic syndrome (MDS) were first treated with two 5-week courses of amifostine alone (each course consisted of 200 mg/m2 of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks). The study patients either had previously failed to respond to treatment with EPO or had pretreatment serum EPO levels of more than 100 mU/ml. None of the patients experienced a complete or partial response in anemia or other cytopenias. We conclude that amifostine alone or in combination with EPO has limited therapeutic activity in MDS.

AB - Ten anemic patients with favorable myelodysplastic syndrome (MDS) were first treated with two 5-week courses of amifostine alone (each course consisted of 200 mg/m2 of the drug given intravenously three times a week for 3 weeks), followed by an additional two courses combined with subcutaneous erythropoietin (EPO) (150 U/kg, three times a week for 8 weeks). The study patients either had previously failed to respond to treatment with EPO or had pretreatment serum EPO levels of more than 100 mU/ml. None of the patients experienced a complete or partial response in anemia or other cytopenias. We conclude that amifostine alone or in combination with EPO has limited therapeutic activity in MDS.

KW - Amifostine

KW - Anemia

KW - Cytopenia

KW - Differentiating therapy

KW - Erythropoietin

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=0035138109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035138109&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(00)00108-9

DO - 10.1016/S0145-2126(00)00108-9

M3 - Article

C2 - 11166835

AN - SCOPUS:0035138109

SN - 0145-2126

VL - 25

SP - 183

EP - 185

JO - Leukemia Research

JF - Leukemia Research

IS - 2

ER -

Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this